Main Article Content
Immunotherapy, Immune checkpoint inhibitors, Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a malignancy with rapidly progressive and poor prognosis. Data from the Thai national public health survey in 2016, liver cancer became the number one leading cause of death. Strategies using immunotherapy, including immune checkpoint inhibitors, have shown promising results as the second-line treatment for advanced HCC after the standard of care and targeted therapy. This review is the update on the important clinical studies, current clinical application, and future perspectives on the immunotherapy in HCC.